‘Building relationships for a better healthcare environment’

On the 24th of August 2001, a group of business and licensing executives united in Basel and founded the Swiss Pharma Licensing Group.  The first Board defined objectives, recruited members and set up the foundation for today’s association.

Read More…

 “DEAL-MAKING IN THE ROUGH“

The Swiss HLG, a non-profit association of Business Development and Licensing professionals, held its 31st  Conference titled “DEAL-MAKING IN THE ROUGH”, in a beautiful setting in the Swiss Alps. The topic of discussion focused on the fact we are living in provoking times: The pharmaceutical and biotech industry as a whole and the professional business developers, alliance managers and dealmakers have to cope with a disruptive and changing environment in which deal making will become more and more complex and ambitious. 

Over two and a half days, more than 85 delegates from Switzerland, Europe, the US and Asia gathered in the Swiss Alps to explore and discuss new trends in partnering and deal-making in the current tumult of our industry with the overall objective to capture the maximum value with professional capabilities and high-calibre talents.

Read More…

Great Offer for Our Swiss HLG Members  

Swiss HLG members €100 DISCOUNT and Start-up Members €150 DISCOUNT off the early bird rate  *limited offer so hurry and register now!

Swiss HLG is happy to introduce the first video of the SCENIC series of the Good Partnering Practice (GPP) initiative: Scouting and Prospecting to support the Business Development professionals during their partnering activities.

Part 1 of the SCENIC series of GPP

“Scouting and Prospecting”

Part 2 of the SCENIC series of GPP

“Evaluation and Due Dilligence

The joint summer conference between the Italian and Swiss Healthcare Licensing Groups took place on the 6th – 7th June in Milan. Over 80 attendees enjoyed the cutting-edge conference on various topics including, The current Italian and Swiss pharmaceutical markets evolution, Partnering in the field of advanced therapies, analysis of 2018 and beginning of 2019 BD&L deals with an interesting discussion about the trends. The artificial intelligence and its impact on BD&L, Business intelligence as a tool to evaluate new BD&L opportunities, Health technology and its impact on the value chain and Trends in the orphan drugs regulations and pricing and pricing of breakthrough therapies in a challenging healthcare system.

Read More…

Join us, become a member !

Join Swiss HLG
as a member

Newsletter

Keep up to date with the latest information by signing up to our newsletter

Why it's worth joining us !

Learn more about Swiss HLG
and our initiatives